All In Biotech

Drug Trial Radar · NCT06005493

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 392 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

392

Planned (sponsor's estimate)

Start

Jul 11, 2023

Primary completion

Mar 16, 2029

Study completion Mar 16, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Conditions

  • Gastric Cancer
  • Gastro-esophageal Junction Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Esophageal Adenocarcinoma

Interventions

  • AZD5863Drug

    T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells

  • AZD2936Drug

    Rilvegostomig is a bi-specific antibody targeting the immunosuppressive PD-1 and TIGIT pathways.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of patients with adverse eventsTime frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
  2. The number of patients with adverse events of special interestTime frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
  3. The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: From first dose of study drug until the end of Cycle 1
  4. The number of patients with serious adverse eventsTime frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
  5. Objective Response Rate (ORR)Time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)

Locations

25 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Shandong, China · Recruiting

  • Research Site

    Toulouse, France · Recruiting

  • Research Site

    Villejuif, France · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Kōtoku, Japan · Recruiting

  • Research Site

    Amsterdam, Netherlands · Recruiting

  • Research Site

    Groningen, Netherlands · Recruiting

  • Research Site

    Rotterdam, Netherlands · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Kaohsiung City, Taiwan · Recruiting

  • Research Site

    Tainan, Taiwan · Recruiting

  • Research Site

    Taoyuan, Taiwan · Recruiting

  • Research Site

    Dundee, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    Metropolitan Borough of Wirral, United Kingdom · Recruiting

  • Research Site

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.